CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: Report of toxicity and treatment results at one year of follow-up in 15 patients

Haematologica

Volumn 88, Issue 3, 2003, Pages 306-314

  Carreras, Enric ^a   Saiz, Albert ^b   Marín, Pedro ^b   Martínez, Carmen ^a   Rovira, Montserrat ^a   Villamor, Neus ^b   Aymerich, Marta ^b   Lozano, Miquel ^b   Fernandez Avilés, Francesc ^a   Urbano Izpizua, Álvaro ^a   Montserrat, Emili ^a   Graus, Francesc ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Autoimmune diseases; Autologous stem cell transplantation; CD34+; Multiple sclerosis; Positive selection

Indexed keywords

CARMUSTINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; MESNA; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ADULT; AUTOTRANSPLANTATION; BLADDER DISEASE; CELL SELECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG TOXICITY; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMIPARESIS; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MULTIPLE SCLEROSIS; NEUTROPENIA; PARAPLEGIA; PERIPHERAL BLOOD STEM CELL; RASH; RECURRENCE RISK; STEM CELL MOBILIZATION; UVEITIS; WEIGHT GAIN;

ADULT; ANTIGENS, CD34; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNE SYSTEM; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0347264750     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359: 1221-31.
2. Noseworthy J, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.
3. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis. Report of the therapeutics and technology assessment subcommittee of the American academy of neurology and the MS council for clinical practice guidelines. Neurology 2002;58:169-78.
4. Hartung H, Gonsette R. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomized, observer-blind phase III trial: clinical results and three year follow-up. Neurology 1999; 52:A290[abstract].
5. Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Int J Hematol 2002;76 Suppl 1:226-47.
6. Openshaw H, Nash RA, McSweeney PA. High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: clinical review. Biol Blood Marrow Transplant 2002;8:233-48.
7. van Bekkum DW. Stem cell transplantation in experimental models of autoimmune diseases. J Clin Immunol 2000;20: 10-6.
8. Ikehara S. Bone marrow transplantation for autoimmune diseases. Acta Haematol 1998;99:116-32.
9. de la Camara R, Bischofberger C, Campins M, Carreras E. Immunization after hematopoietic stem cell transplantation: review and recommendations. Subcommittee of the Spanish Group on Infectious Complications in Hematopoietic Transplantation (GETH) and the Spanish Society of Preventive Medicine, Public Health and Hygiene. Med Clin (Barc) 1998;110:146-55.
10. Bearman SI, Appelbaum FR, Back A, Petersen FB, Buckner CD, Sullivan KM, et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989;7:1288-94.
11. Saiz A, Carreras E, Berenguer J, Yague J, Martinez C, Marin P, et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology 2001;56:1084-9.
12. Martinez C, Urbano-Ispizua A, Rovira M, Carreras E, Rozman C, Montserrat E. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation. Leuk Lymphoma 2000;37:535-42.
13. Fassas A, Passweg J, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E, et al. Hematopoietic stem cell transplantation for multiple sclerosis: a retrospective multicenter study. J Neurol 2002;249:1088-97.
14. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, et al. Autologous stem cell transplantation in progressive multiple sclerosis - an interim analysis of efficacy. J Clin Immunol 2000;20:24-30.
15. Burt RK, Traynor A, Pope R, Schroeder J, Cohen B, Karlin KH, et al. Treatment of autoimmune diseases by intensive immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998;92:3505-14.
16. Mandalfino P, Rice G, Smith A, Klein JL, Rystedt L, Ebers GC. Bone marrow transplantation in multiple sclerosis. J Neurol 2000;247:691-5.
17. Kozak T, Havrdova E, Pit'ha J, Gregora E, Pytlik R, Maaloufova J, et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000;25:525-31.
18. Openshaw H, Lund BT, Kashyap A, Atkinson R, Sniecinski I, Weiner LP, et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000;6:563-75.
19. Mancardi GL, Saccardi R, Filippi M, Gualandi F, Murialdo A, Inglese M, et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 2001;57:62-8.
20. To LB, Roberts MM, Haylock DN, Dyson PG, Branford AL, Thorp D, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992;9:277-84.
21. Openshaw H, Stuve O, Antel JP, Nash R, Lund BT, Weiner LP, et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000;54: 2147-50.
22. Burt RK, Fassas A, Snowden J, van Laar JM, Kozak T, Wulffraat NM, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant 2001;28:1-12.
23. van Gelder M, van Bekkum DW. Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain. Bone Marrow Transplant 1995;16:343-51.
24. Openshaw H, Hinton DR, Slatkin NE, Bierman PJ, Hoffman FM, Snyder DS. Exacerbation of inflammatory demyelinating polyneuropathy after bone marrow transplantation. Bone Marrow Transplant 1991;7:411-4.
25. Chiang CS, McBride WH. Radiation enhances tumor necrosis factor α production by murine brain cells. Brain Res 1991;566:265-9.
26. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in autoimmune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997;19:643-5.
27. Comi G, Kappos L, Clanet M, Ebers G, Fassas A, Fazekas F, et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. J Neurol 2000;247:376-82.
28. Weiss RB, Issell BF. The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). Cancer Treat Rev 1982;9:313-30.
29. Oyama Y, Cohen B, Traynor A, Brush M, Rodriguez J, Burt RK. Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplant 2002; 29:81-5.
30. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immuno-therapy after autologous hemopoietic stem cell transplantation. Blood 1998;92:1471-90.
31. Talmadge JE, Reed E, Ino K, Kessinger A, Kuszynski C, Heimann D, et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 1997;19:161-72.
32. Mackall C, Granger L, Sheard M, Cepeda R, Gress R. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood 1993;82:2585-94.
33. + T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
34. +-enriched versus non T cell-depleted autologous peripheral blood stem cell transplantation. J Hematother Stem Cell Res 2000;9:727-36.
35. Anderson KC, Soiffer R, deLage R, Takvorian T, Freedman AS, Rabinowe SL, et al. T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications. Blood 1990;76:235-44.
36. Miyamoto T, Gondo H, Miyoshi Y, Shigematsu H, Minematsu T, Takenaka K, et al. Early viral complications following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Br J Haematol 1998;100:348-50.